Our Pipeline
Our clinical development programs have the potential to address numerous immune-mediated diseases that impact large patient populations with limited therapeutic options.
STAGE OF DEVELOPMENT
Indication(s)
Pre-Clinical
IND-Enabling
Phase 1
Phase 2
Phase 3
Candidate
*Worldwide rights outside of Greater China. IV=intravenous, SC=subcutaneous, mAB=monoclonal antibody
Scientific approach
We develop differentiated monoclonal antibodies for immune-mediated diseases.
Clinical trials
Our investigational therapies have the potential to address immune-mediated diseases impacting patients with limited therapeutic options.